首页> 外文期刊>Scandinavian journal of infectious diseases. >Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria
【24h】

Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria

机译:磷霉素:对抗多药耐药细菌引起的感染的功效

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To analyze the indications for and the efficacy of parenteral fosfomycin, especially against multidrug-resistant (MDR) and pan-resistant bacterial infections.Patients and methods: During a unique crisis in fosfomycin production, the supply of this antibiotic had to be carefully monitored in France over a 10-week period. One hundred and sixteen assessable patients were included in a prospective cohort study.Results: The main indications for use were osteoarthritis, lung infection, urinary tract infection, and bacteraemia. The 2 bacteria most frequently involved were Pseudomonas aeruginosa and methicillin-resistant Staphylococcus. MDR bacteria were seen in 71.5% (83/116) of cases, especially MDR P. aeruginosa (n = 28). Critical situations were common, with 44.0% (51/116) of hospitalizations occurring in an intensive care unit and 22.4% (26/116) of patients with septic shock. The overall outcome was favourable in 76.8% of cases (76/99 assessable patients).Conclusion: This study provided a unique opportunity to describe the use of fosfomycin and assess its efficacy, especially against MDR bacterial infections, even in critical situations.
机译:目的:分析非农磷霉素的适应症和疗效,特别是针对多药耐药(MDR)和泛耐药菌感染的患者。方法和方法:在磷霉素生产的独特危机中,必须谨慎地使用这种抗生素在法国进行了为期10周的监控。结果前瞻性队列研究共纳入116例可评估患者。结果:使用的主要适应症是骨关节炎,肺部感染,尿路感染和菌血症。最常涉及的2种细菌是铜绿假单胞菌和耐甲氧西林的葡萄球菌。在71.5%(83/116)的病例中发现了耐多药细菌,尤其是耐多药铜绿假单胞菌(n = 28)。危急情况很常见,重症监护病房住院率为44.0%(51/116),败血性休克患者为22.4%(26/116)。总体结果在76.8%的病例(76/99名可评估患者)中是有利的。结论:这项研究提供了一个独特的机会来描述磷霉素的使用并评估其疗效,尤其是在危急情况下尤其针对MDR细菌感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号